Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID‐19: A Retrospective Multicenter Study in the United States
Many academic institutions are collecting blood samples from patients seeking treatment for coronavirus disease 2019 (COVID‐19) to build research biorepositories. It may be feasible to extract pharmacogenomic (PGx) information from biorepositories for clinical use. We sought to characterize the pote...
Saved in:
Main Authors: | James M. Stevenson (Author), G. Caleb Alexander (Author), Natasha Palamuttam (Author), Hemalkumar B. Mehta (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Race, Ethnicity, and Pharmacogenomic Variation in the United States and the United Kingdom
by: Shivam Sharma, et al.
Published: (2023) -
Editorial: The utilization of bench-to-bedside approaches in pharmacogenomics
by: Eric Rytkin, et al.
Published: (2023) -
Clinical utility of pharmacogenomics in the management of hepatitis C
by: Trinks J, et al.
Published: (2014) -
Clinical Utility and Implementation of Pharmacogenomics for the Personalisation of Antipsychotic Treatments
by: Marta Hernandez, et al.
Published: (2024) -
No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study
by: Takahashi PY, et al.
Published: (2021)